Browsing articles in "ADHD"


A Potential New Non-Stimulant Treatment Option For ADHD
November 27, 2023   

Encouraging outcomes from two Phase 3 clinical trials assessing the efficacy of centanafadine, an investigational compound designed to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents..
 Continue reading
Highlights from 2023 NEI Congress: Sessions on ADHD
November 11, 2023   

Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder characterized by symptoms of inattention, hyperactivity, and impulsivity that negatively impact daily functioning...
 Continue reading
ADHD as a Risk Factor For Being Involved in Intimate Partner Violence
October 12, 2023   

In this systematic review and meta-analysis of 14 studies including over 1 million individuals, researchers investigated the relationships between ADHD and violence. The authors found that individuals with ADHD are more likely to be involved in both IPV...
 Continue reading
FDA Approves Multiple Generics of ADHD and BED Treatment
August 28, 2023   

The U.S. Food and Drug Administration has approved several first generics of Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets for attention-deficit/hyperactivity disorder (ADHD) in patients six years and older and moderate to severe binge-eating disorder (BED) in adults...
 Continue reading
Childhood Adversity and the Cortisol Awakening Response in Depression
August 3, 2023   

The hypothalamic pituitary adrenal (HPA) axis is the main regulator of our response to stress (Figure). Numerous studies and years of research have shown that dysregulation of the HPA axis is highly associated with depression. In healthy individuals, cortisol acts on glucocorticoid receptors to exert a negative feedback control whereby the HPA axis is quieted. In individuals with depression, there seems to be a lack of this negative feedback ....
 Continue reading (Members only)
Stimulant Treatment in Youth Not Associated With Substance Use Later in Life
July 16, 2023   

Childhood attention-deficit/hyperactivity disorder (ADHD) is linked to elevated substance use and substance use disorder (SUD) in adulthood. Stimulant medications are commonly used to treat ADHD and are thought to reduce substance use due to their efficacy in controlling impulsivity. However, early exposure to stimulants may sensitize individuals to other drugs and increase the risk of harmful substance use...
 Continue reading
Long-Term Safety of Methylphenidate in Children and Adolescents with ADHD
April 29, 2023   

Methylphenidate (MPH) is the most frequently prescribed treatment for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents; however, data on long-term safety are limited. A naturalistic, longitudinal, controlled, multi-site study assessed the safety of MPH over 2 years in participants aged 6–17 years old....
 Continue reading (Members only)
Risk of Cardiovascular Diseases Associated With Medications Used in ADHD
December 19, 2022   

In a recent cohort study, the relationship benzodiazepines versus alternative medications prescribed for sleep disorders and increased risk of drug overdose in adolescents was examined. The study included participants diagnosed with a sleeping disorder between the age of 10 to 29 years of age between January...
 Continue reading
ADHD Polygenic Risk Scores Impact On Outcomes
October 25, 2022   

Early identification of ADHD is critical when it comes to mitigating negative developmental consequences associated with the disorder. However, this can be especially difficult and there are currently no concrete biomarkers used to diagnose ADHD. A recent ...
 Continue reading
Adult ADHD Linked To Elevated Risk Of Cardiovascular Diseases
October 10, 2022   

The cardiovascular safety of attention-deficit/hyperactivity disorder (ADHD) medications has been studied previously with mixed findings, in part due to study bias. A recent systematic review and meta-analysis examined observational studies that investigated the association between ADHD medications (stimulants and nonstimulants) and cardiovascular disease (CVD). Using rigorous quality assessment to account for bias, 19 studies with 3,931,532 participants ...
 Continue reading (Members only)
Top of Page